Author

J. T. Maricato

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:protein structure· 1

Frequent Co-Authors

A. S. Llera· 1 shared A. Soto· 1 shared C. Torres-Braconi· 1 shared D. Aguilar-Cortes· 1 shared E. G. A. Cafferata· 1 shared F. J. Nunez· 1 shared G. D. Rios· 1 shared H. H. Hortega· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. S. Llera

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development and characterization of a multimeric recombinant protein based on the spike protein receptor binding domain of SARS-CoV-2 that can neutralize virus infection

V. A. de Lima, R. d. S. Ferreira, M. L. V. Oliva, R. Andreata-Santos, L. M. R. Janini, J. T. Maricato, M. A. Akamatsu, P. L. Ho, S. Schenkman

This paper develops a multimeric recombinant protein based on the SARS-CoV-2 spike protein RBD that neutralizes virus infection by inhibiting ACE2 binding.

bioRxiv · Feb 15, 2023 · PreprintMicrobiology

A single shot of a hybrid hAdV5-based anti-COVID-19 vaccine induces a long-lasting immune response and broad coverage against VOC

M. V. Lopez, S. E. Vinzon, E. G. A. Cafferata, F. J. Nunez, A. Soto, M. Sanchez-Lamas, J. Afonso, D. Aguilar-Cortes, G. D. Rios, J. T. Maricato, C. Torres-Braconi, V. Barbosa-da Silveira, T. Montes-de Andrade, T. Carvalho-de Souza Bonetti, L. M. Ramos Janini, , O. L. Podhajcer

This paper describes a single-dose hybrid hAdV5-based vaccine that induces long-lasting immunity and broad neutralization against SARS-CoV-2 variants.

bioRxiv · Aug 11, 2021Immunology